Lantern Pharma Launches AI-Powered ZetaOmics Platform to Advance Precision Oncology Research

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. This new module introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry, and company collaborators, the platform aims to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.

According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute, and validate biological analyses, detect potential flaws in experimental design, and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for bioinformatics analysis, enabling researchers to focus on interpreting results and generating hypotheses. The platform's ability to automatically detect errors and ensure reproducibility addresses a critical need in biomedical research, where data analysis inconsistencies can lead to unreliable findings.

Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations. This move positions Lantern to generate a new revenue stream from its AI platform, complementing its clinical pipeline of cancer therapies. The full press release is available at https://ibn.fm/9sIIl.

The launch of ZetaOmics underscores the growing trend of integrating artificial intelligence into oncology research. By automating complex bioinformatics tasks, the platform could accelerate the discovery of biomarkers and therapeutic targets, ultimately leading to more personalized cancer treatments. For Lantern, which already leverages its proprietary RADR platform for drug development, ZetaOmics represents a strategic expansion into the broader biomedical research market.

Lantern Pharma is a clinical-stage precision oncology company with a pipeline that includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300 (cisplatin/ethacraplatin analog), the latter being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. More information about Lantern Pharma is available in its newsroom at https://ibn.fm/LTRN.

The implications of ZetaOmics are significant for the field of precision oncology. By providing researchers with a robust, automated tool for multi-omic analysis, the platform could democratize access to advanced bioinformatics, enabling smaller institutions to conduct high-quality research. Moreover, the emphasis on reproducibility and audit trails aligns with broader efforts to improve scientific rigor. As Lantern expands its commercial offerings, it may also attract collaborations that further validate its AI capabilities and drive adoption across the industry.